Collateral Sensitivity to Fosfomycin of Tobramycin-Resistant Mutants of
Pseudomonas aeruginosa
antibiotic resistance
bacterial evolution
collateral sensitivity
evolution contingency
fosfomycin
tobramycin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
09
02
2023
revised:
16
03
2023
accepted:
04
04
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Understanding the consequences in bacterial physiology of the acquisition of drug resistance is needed to identify and exploit the weaknesses derived from it. One of them is collateral sensitivity, a potentially exploitable phenotype that, unfortunately, is not always conserved among different isolates. The identification of robust, conserved collateral sensitivity patterns is then relevant for the translation of this knowledge into clinical practice. We have previously identified a robust fosfomycin collateral sensitivity pattern of
Identifiants
pubmed: 37108055
pii: ijms24086892
doi: 10.3390/ijms24086892
pmc: PMC10138353
pii:
doi:
Substances chimiques
Tobramycin
VZ8RRZ51VK
Fosfomycin
2N81MY12TE
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MCIN/AEI/10.13039/501100011033
ID : PID2020-113521RB-I00
Références
Front Genet. 2018 Oct 18;9:451
pubmed: 30405685
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28893783
Microb Biotechnol. 2022 Feb;15(2):613-629
pubmed: 33960651
J Med Microbiol. 2011 Mar;60(Pt 3):329-336
pubmed: 21212150
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
J Bacteriol. 1952 Oct;64(4):489-99
pubmed: 12999676
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9767-9772
pubmed: 30209218
Front Microbiol. 2018 Apr 06;9:685
pubmed: 29681898
Ann N Y Acad Sci. 1974 May 10;235(0):364-86
pubmed: 4605290
Nat Rev Microbiol. 2021 May;19(5):331-342
pubmed: 33214718
Microbiol Spectr. 2022 Aug 31;10(4):e0024722
pubmed: 35766499
Talanta. 2005 Mar 15;65(5):1215-20
pubmed: 18969934
Antimicrob Agents Chemother. 2015 Oct;59(10):6039-45
pubmed: 26195514
J Bacteriol. 2003 Feb;185(4):1218-28
pubmed: 12562791
Sci Adv. 2020 Aug 05;6(32):eaba5493
pubmed: 32821825
Mol Biol Evol. 2017 Sep 1;34(9):2229-2244
pubmed: 28541480
Nat Ecol Evol. 2021 May;5(5):677-687
pubmed: 33664488
Nat Microbiol. 2019 Sep;4(9):1432-1442
pubmed: 31439928
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4229-36
pubmed: 27139485
J Bacteriol. 2009 Nov;191(22):6968-74
pubmed: 19734311
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
Antimicrob Agents Chemother. 2012 Dec;56(12):6349-57
pubmed: 23045355
Appl Environ Microbiol. 2015 Feb;81(3):890-9
pubmed: 25416762
Int J Antimicrob Agents. 2020 Dec;56(6):106196
pubmed: 33045347
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30082283
Trends Microbiol. 2015 Jul;23(7):401-7
pubmed: 25818802
Mol Biol Evol. 2021 May 4;38(5):2057-2069
pubmed: 33480997
Curr Opin Microbiol. 2009 Oct;12(5):476-81
pubmed: 19716760
mBio. 2017 Mar 28;8(2):
pubmed: 28351914
Curr Opin Microbiol. 2021 Dec;64:125-132
pubmed: 34710741
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14494-9
pubmed: 25246554
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Nat Commun. 2018 Sep 10;9(1):3673
pubmed: 30202004
Nat Rev Microbiol. 2022 Aug;20(8):478-490
pubmed: 35241807
Nat Chem Biol. 2013 Aug;9(8):491-3
pubmed: 23831760
Mol Biol Evol. 2022 Mar 2;39(3):
pubmed: 35291010
PLoS Pathog. 2021 Jan 14;17(1):e1009172
pubmed: 33444399
PLoS Biol. 2018 Apr 30;16(4):e2004356
pubmed: 29708964
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):
pubmed: 28062557
Mol Syst Biol. 2013 Oct 29;9:700
pubmed: 24169403
Microb Drug Resist. 2014 Jun;20(3):231-7
pubmed: 24819062
Microbiol Spectr. 2023 Feb 14;11(1):e0227622
pubmed: 36533961
mBio. 2017 Mar 28;8(2):
pubmed: 28351916
Clin Infect Dis. 2008 Dec 15;47(12):1526-33
pubmed: 18990062